Roginolisib

N/A

Report date: 2026/04/28 20:00:22
NME

Base Information

Drug NameRoginolisib
Drug Alias NameIOA-244
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase delta inhibitorsT lymphocytes inhibitorsProtein allosteric inhibitors
TargetsPhosphatidylinositol 3 kinase delta
Therapy Area/IndicationsUveal melanomaSolid tumoursPrimary Myelofibrosis +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesItaly +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesIonctura Sa
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteIonctura SaSt Vincent'S Hospital, Sydney
Inactive CompaniesN/A
Active IndicationsUveal melanomaSolid tumoursPrimary Myelofibrosis +[9] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksDrugBank